Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
TBPH Transcript
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript
Positive11-11
The earnings call highlighted strong financial performance with YUPELRI's sales growth and a robust cash position. The company's strategic focus on the CYPRESS study and potential ampreloxetine launch is promising, despite some regulatory risks. The Q&A revealed confidence in study design and operational execution, with analysts showing interest in future capital returns and pipeline evaluations. Overall, the positive financial metrics, strategic milestones, and optimistic outlook outweigh the risks, suggesting a positive stock price movement.
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call summary indicates strong financial performance, with significant growth in hospital volume, collaboration revenue, and a solid cash position. The Q&A section reveals management's strategic focus on improving YUPELRI's channel mix and addressing payer perspectives for ampreloxetine. Despite some uncertainties in the timeline and pricing, overall sentiment remains positive due to strong revenue growth and financial health. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects
Neutral4-11
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture: strong YUPELRI sales growth and potential milestone payments are positive, but financial risks and supply chain challenges could dampen enthusiasm. The Q&A section reveals some uncertainty about hospital performance and regulatory timelines, which tempers optimism. Despite the company's commitment to shareholder returns, the lack of clear guidance on certain issues and typical seasonality concerns suggest a cautious market reaction, leading to a neutral sentiment.
TBPH Slides
TBPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
